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Background
We developed a primary human monocyte-derived mac-
rophage (MDM) HIV-1 infection model to examine
human (2F5 IgM, 4E10, 2G12) and murine multispecific
(WR301, WR304A, and WR320) IgM mAbs for their bind-
ing and neutralization abilities. The murine mAbs exhibit
either lipid or both HIV-protein and lipid specificities.
The murine and two of the human mAbs (2F5, 2G12)
were also tested for binding to TZM-bl, HeLa, Jurkat, and
primary T cells and for chemokine production.
Methods
MDM were isolated and purified from PBMC. After 5 days
of growth, the cells were >97% CD14 and CD163 posi-
tive. Binding of mAbs to cells was analyzed by immun-
ofluorescence and flow cytometry, and the production of
chemokines was measured by ELISA. To assess antibody-
mediated neutralization, purified 91US_1 virus was pre-
incubated with the human mAbs for 1 h and then added
to MDM for 3 h. The cells were washed and cultured for
96 h followed by measurement of p24 in the media and
in the cell lysates.
Results
The binding of murine mAbs (<4.8 pg endotoxin/μg
mAb) to MDM, TZM-bl, Jurkat, and primary T cells was
dose-dependent and steric hinderance observed at low
doses could be overcome at high doses of the antibody. A
dose-dependent increase in the production of MIP-1α and
MIP-1β was obtained only from MDM, with maximum
levels observed at 24 h post-mAb stimulation. The results
were different with the human mAbs. 2G12 did not bind
to MDM. 2F5 (IgM) bound to Jurkat cells and exhibited
low binding (<10%) to MDM, TZM-bl, and T cells. A pro-
ductive infection was obtained in MDM with 91US_1,
which could be neutralized by the human mAbs.
Conclusion
We have set up a MDM infection model to demonstrate
the induction of protective chemokines and to evaluate
the ability of the murine mAbs to neutralize HIV-1 in the
MDM system.
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